ERBB2 and cancer: In this context, HER3 has been associated with the acquisition of drug resistance to anti‐EGFR (HER1) and anti‐HER2 cancer therapy,11, 42 and MET is involved in the proliferation, migration, invasion, and motility43, 44, 45 of cancer cells.